-
Your selected country is
United Kingdom
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Western blot analysis of AP180 on a rat cerebrum lysate. Lane 1: 1:250, lane 2: 1:500, lane 3: 1:1000 dilution of the mouse anti-AP180 antibody.
Immunofluorescence staining of human endothelial cells.
BD Transduction Laboratories™ Purified Mouse Anti-AP180
BD Transduction Laboratories™ Purified Mouse Anti-AP180
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
Western blot: Please refer to http://www.bdbiosciences.com/pharmingen/protocols/Western_Blotting.shtml
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
Companion Products
AP180, also known as AP-3, F1-20, NP185, and pp155, is one of four assembly proteins which are involved in the organization and assembly of clathrin triskelia in clathrin-coated vesicles. Two of these proteins, AP-1 and AP-2, exist as tetramers, while AP180 and auxilin are monomeric assembly proteins. The clathrin binding potential of AP180 is defined by several regions of the molecule, including the 30 kDa N-terminal domain, a central domain, and a 58 kDa C-terminal domain. Although clathrin binding occurs throughout the molecule, only the C-terminal domain is associated with both binding of clathrin and assembly of clathrin cages. The highly acidic central domain, which contains an uncharged alanine-rich segment, is thought to impart the irregular physical properties to this protein. AP180 is the only clathrin assembly protein specific for synapses and is thought to be involved in synaptic vesicle biogenesis and recycling. Furthermore, AP180 is bound by inositol-6-phosphate which has been shown to be closely regulated in neuronal cells by external stimuli.
Development References (5)
-
Drake MT, Traub LM. Interaction of two structurally distinct sequence types with the clathrin terminal domain beta-propeller. J Biol Chem. 2001; 276(31):28700-28709. (Biology: Western blot). View Reference
-
Kalthoff C, Groos S, Kohl R, Mahrhold S, Ungewickell EJ. Clint: a novel clathrin-binding ENTH-domain protein at the Golgi. Mol Biol Cell. 2002; 13(11):4060-4073. (Biology: Immunofluorescence). View Reference
-
Morris SA, Schroder S, Plessmann U, Weber K, Ungewickell E. Clathrin assembly protein AP180: primary structure, domain organization and identification of a clathrin binding site. EMBO J. 1993; 12(2):667-675. (Biology). View Reference
-
Traub LM, Downs MA, Westrich JL, Fremont DH. Crystal structure of the alpha appendage of AP-2 reveals a recruitment platform for clathrin-coat assembly. Proc Natl Acad Sci U S A. 1999; 96(16):8907-8912. (Biology: Western blot). View Reference
-
Ye W, Lafer EM. Clathrin binding and assembly activities of expressed domains of the synapse-specific clathrin assembly protein AP-3. J Biol Chem. 1995; 270(18):10933-10939. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.